Zenas BioPharma, Inc.
ZBIO
$7.54
-$0.26-3.33%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 140.75% | 258.53% | 126.65% | 47.55% | 27.83% |
| Gross Profit | -116.27% | -182.49% | -126.65% | -47.55% | -27.83% |
| SG&A Expenses | 162.92% | 48.37% | 47.74% | 31.93% | 35.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.65% | 185.09% | 110.00% | 44.49% | 30.49% |
| Operating Income | -124.48% | -215.05% | -110.00% | -44.49% | -30.49% |
| Income Before Tax | -114.84% | -208.42% | -30.74% | -45.57% | -27.86% |
| Income Tax Expenses | 42.52% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -113.95% | -208.42% | -30.74% | -45.57% | -29.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -113.95% | -208.42% | -30.74% | -45.57% | -29.45% |
| EBIT | -124.48% | -215.05% | -110.00% | -44.49% | -30.49% |
| EBITDA | -124.62% | -214.86% | -110.13% | -44.53% | -30.51% |
| EPS Basic | 92.13% | -307.18% | -1,409.45% | -41.65% | -26.10% |
| Normalized Basic EPS | 92.13% | -121.66% | -95.02% | -41.65% | -23.02% |
| EPS Diluted | 92.13% | -356.12% | -1,411.08% | -41.65% | -26.10% |
| Normalized Diluted EPS | 92.13% | -126.74% | -95.02% | -41.65% | -23.02% |
| Average Basic Shares Outstanding | 2,620.21% | 400.53% | 2.23% | 2.77% | 2.65% |
| Average Diluted Shares Outstanding | 2,620.21% | 305.48% | 2.23% | 2.77% | 2.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
